Bayer halts vilaprisan drug trials due to toxicology data


FRANKFURT (Reuters) – Bayer said it halted trials testing its experimental uterine fibroids treatment vilaprisan, which it previously expected to generate peak annual sales of more than 1 billion euros ($1.1 billion), citing the risk of side effects.

“For vilaprisan we have just some days ago put clinical development of our ongoing trials on hold,” said drug development head Joerg Moeller, speaking at the group’s capital markets day in London.

“That is due to very recent safety findings in long-term toxicology studies … We have therefore decided as a precautionary measure to stop enrolment into our ongoing program and evaluate the data,” he added.